Trial Profile
Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CAPTEM
- 07 Nov 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
- 07 Nov 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2026.
- 30 Aug 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2024.